Sun Pharma launches Drizalma Sprinkle in US
Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor (SNRI) designed for the treatment of various neuro-psychiatric and pain disorders in patients who have difficulty swallowing – a
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
Over time, patients taking levodopa may begin to experience periods when PD symptoms, including motor fluctuations, re-emerge between treatment doses. These are called “off” episodes. “We are pleased